SUBSCRIBE
SUBSCRIBE
News   Drug Development

Disease-Modifying Drug May Slow Alzheimer’s Disease; Tarenflurbil Lessened Decline In Functional Ability, British Study Concludes

April 30, 2008 | 
1 min read

NEW YORK (Reuters Health) - The results of a clinical trial suggest that a new drug slows the functional decline seen in patients with mild Alzheimer’s disease, according to a report in the online issue of The Lancet Neurology.

Clinical research Phase II Phase III Europe
MORE ON THIS TOPIC
ASD autism neurodevelopmental spectrum disorder, deficits in social communication and interaction, brain with impairment, hypersensitivity and abnormalities
Neuroscience
Epilepsy Biotech Nabs up to $570M in Deal With Italy’s Angelini Plus $140M Fundraising
May 27, 2025
 · 
1 min read
 · 
Annalee Armstrong
Red round circle with a pause button or icon against yellow background.
Gene therapy
Rocket’s Danon Disease Gene Therapy on Hold After Patient Death
May 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Syndeio CEO Derek Small,
Funding
Karuna, Naurex Alumni Launch New Biotech to Modulate Synaptic Plasticity for Neuro Diseases
May 27, 2025
 · 
3 min read
 · 
Heather McKenzie
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Rare diseases
Prothena Looks at Business Options as Phase III AL Amyloidosis Trial Fails
May 27, 2025
 · 
2 min read
 · 
Tristan Manalac